Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pacific Edge Limited ( (PFGTF) ) just unveiled an update.
Pacific Edge Limited announced that its Chairman, Chris Gallaher, will seek re-election at the upcoming Annual Shareholders’ Meeting to ensure leadership continuity as the company navigates the loss of Medicare coverage for its Cxbladder products. The inclusion of Cxbladder Triage in the American Urological Association’s guidelines offers a new perspective on pursuing re-coverage. The company has also opened nominations for new directors, emphasizing the importance of stability and strategic leadership during this transitional phase.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. Headquartered in Dunedin, New Zealand, the company offers its Cxbladder suite of non-invasive genomic urine tests for patients with hematuria or those under surveillance for recurrent disease. These tests are available globally, including in the US, Australasia, Israel, and various markets in Asia and South America.
Learn more about PFGTF stock on TipRanks’ Stock Analysis page.